Human adult mesenchymal stem cells (MSCs) support the engineering of functional tissue constructs by secreting angiogenic and cytoprotective factors, which act in a paracrine fashion to influence cell survival and vascularization. MSCs have been isolated from many different tissue sources, but little is known about how paracrine factor secretion varies between different MSC populations. We evaluated paracrine factor expression patterns in MSCs isolated from adipose tissue (ASCs), bone marrow (BMSCs), and dermal tissues [dermal sheath cells (DSCs) and dermal papilla cells (DPCs)]. Specifically, mRNA expression analysis identified insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor-D (VEGF-D), and interleukin-8 (IL-8) to be expressed at higher levels in ASCs compared with other MSC populations whereas VEGF-A, angiogenin, basic fibroblast growth factor (bFGF), and nerve growth factor (NGF) were expressed at comparable levels among the MSC populations examined. Analysis of conditioned media (CM) protein confirmed the comparable level of angiogenin and VEGF-A secretion in all MSC populations and showed that DSCs and DPCs produced significantly higher concentrations of leptin. Functional assays examining in vitro angiogenic paracrine activity showed that incubation of endothelial cells in ASCCM resulted in increased tubulogenic efficiency compared with that observed in DPCCM. Using neutralizing antibodies we concluded that VEGF-A and VEGF-D were 2 of the major growth factors secreted by ASCs that supported endothelial tubulogenesis. The variation in paracrine factors of different MSC populations contributes to different levels of angiogenic activity and ASCs maybe preferred over other MSC populations for augmenting therapeutic approaches dependent upon angiogenesis.
Get full access to this article
View all access options for this article.
References
1.
JohnstonIA. 1982. Capillarisation, oxygen diffusion distances and mitochondrial content of carp muscles following acclimation to summer and winter temperatures. Cell Tissue Res, 222:325–337.
2.
ZukPA, ZhuM, AshjianP, De UgarteDA, HuangJI, MizunoH, AlfonsoZC, FraserJK, BenhaimP, HedrickMH. 2002. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell, 13:4279–4295.
3.
HaynesworthSE, GoshimaJ, GoldbergVM, CaplanAI. 1992. Characterization of cells with osteogenic potential from human marrow. Bone, 13:81–88.
4.
YooJU, BarthelTS, NishimuraK, SolchagaL, CaplanAI, GoldbergVM, JohnstoneB. 1998. The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. J Bone Joint Surg Am, 80:1745–1757.
5.
ChoiYS, DustingGJ, StubbsS, ArunothayarajS, HanXL, CollasP, MorrisonWA, DilleyRJ. 2010. Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J Cell Mol Med, 14:878–889.
6.
NaritaY, YamawakiA, KagamiH, UedaM, UedaY. 2008. Effects of transforming growth factor-beta 1 and ascorbic acid on differentiation of human bone-marrow-derived mesenchymal stem cells into smooth muscle cell lineage. Cell Tissue Res, 333:449–459.
7.
StudenyM, MariniFC, DembinskiJL, ZompettaC, Cabreira-HansenM, BekeleBN, ChamplinRE, AndreeffM. 2004. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst, 96:1593–1603.
8.
WangQ, SunB, WangD, JiY, KongQ, WangG, WangJ, ZhaoW, JinL, LiH. 2008. Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand J Immunol, 68:607–615.
9.
KofidisT, de BruinJL, YamaneT, TanakaM, LeblDR, SwijnenburgRJ, WeissmanIL, RobbinsRC. 2005. Stimulation of paracrine pathways with growth factors enhances embryonic stem cell engraftment and host-specific differentiation in the heart after ischemic myocardial injury. Circulation, 111:2486–2493.
10.
LiL, ZhangS, ZhangY, YuB, XuY, GuanZ. 2009. Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. Mol Biol Rep, 36:725–731.
11.
ShabbirA, ZisaD, LinH, MastriM, RoloffG, SuzukiG, LeeT. 2010. Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair. Am J Physiol Heart Circ Physiol, 299:H1428–H1438.
12.
KinnairdT, StabileE, BurnettMS, LeeCW, BarrS, FuchsS, EpsteinSE. 2004. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res, 94:678–685.
13.
HoffmannJ, GlassfordAJ, DoyleTC, RobbinsRC, SchrepferS, PelletierMP. 2010. Angiogenic effects despite limited cell survival of bone marrow-derived mesenchymal stem cells under ischemia. Thorac Cardiovasc Surg, 58:136–142.
14.
NguyenBK, MaltaisS, PerraultLP, TanguayJF, TardifJC, StevensLM, BorieM, HarelF, MansourS, NoiseuxN. 2010. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res, 3:547–558.
ZhangX, HiraiM, CanteroS, CiubotariuR, DobrilaL, HirshA, IguraK, SatohH, YokomiIet al. 2011. Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. J Cell Biochem, 112:1206–1218.
18.
JahodaCA, OliverRF. 1984. Vibrissa dermal papilla cell aggregative behaviour in vivo and in vitro. J Embryol Exp Morphol, 79:211–224.
19.
WagnerW, WeinF, SeckingerA, FrankhauserM, WirknerU, KrauseU, BlakeJ, SchwagerC, EcksteinV, AnsorgeW, HoAD. 2005. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol, 33:1402–1416.
20.
NiemeyerP, KornackerM, MehlhornA, SeckingerA, VohrerJ, SchmalH, KastenP, EcksteinV, SudkampNP, KrauseU. 2007. Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro. Tissue Eng, 13:111–121.
21.
PuissantB, BarreauC, BourinP, ClavelC, CorreJ, BousquetC, TaureauC, CousinB, AbbalMet al. 2005. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol, 129:118–129.
22.
LiuTM, MartinaM, HutmacherDW, HuiJH, LeeEH, LimB. 2007. Identification of common pathways mediating differentiation of bone marrow- and adipose tissue-derived human mesenchymal stem cells into three mesenchymal lineages. Stem Cells, 25:750–760.
23.
NiemeyerP, FechnerK, MilzS, RichterW, SuedkampNP, MehlhornAT, PearceS, KastenP. 2010. Comparison of mesenchymal stem cells from bone marrow and adipose tissue for bone regeneration in a critical size defect of the sheep tibia and the influence of platelet-rich plasma. Biomaterials, 31:3572–3579.
24.
IkegameY, YamashitaK, HayashiSI, MizunoH, TawadaM, YouF, YamadaK, TanakaY, EgashiraYet al. 2011. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy, 13:13.
25.
KimY, KimH, ChoH, BaeY, SuhK, JungJ. 2007. Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem, 20:867–876.
26.
JahodaC, OliverRF. 1981. The growth of vibrissa dermal papilla cells in vitro. Br J Dermatol, 105:623–627.
27.
MagerlM, KauserS, PausR, TobinDJ. 2002. Simple and rapid method to isolate and culture follicular papillae from human scalp hair follicles. Exp Dermatol, 11:381–385.
28.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD, HorwitzE. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
29.
CheungCY. 1997. Vascular endothelial growth factor: possible role in fetal development and placental function. J Soc Gynecol Investig, 4:169–177.
30.
IshizawaK, KuboH, YamadaM, KobayashiS, SuzukiT, MizunoS, NakamuraT, SasakiH. 2004. Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. Biochem Biophys Res Commun, 324:276–280.
PengL, JiaZ, YinX, ZhangX, LiuY, ChenP, MaK, ZhouC. 2008. Comparative analysis of mesenchymal stem cells from bone marrow, cartilage, and adipose tissue. Stem Cells Dev, 17:761–773.
33.
MaumusM, PeyrafitteJ-A, D'AngeloR, Fournier-WirthC, BouloumieA, CasteillaL, SengeneC, BourinP. 2011. Native human adipose stromal cells: localization, morphology and phenotype. Int J Obesity, 35:1141–1153.
34.
GiordanoFJ, GerberHP, WilliamsSP, VanBruggenN, BuntingS, Ruiz-LozanoP, GuY, NathAK, HuangYet al. 2001. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A, 98:5780–5785.
35.
LiuY, SongZ, ZhaoY, QinH, CaiJ, ZhangH, YuT, JiangS, WangG, DingM, DengH. 2006. A novel chemical-defined medium with bFGF and N2B27 supplements supports undifferentiated growth in human embryonic stem cells. Biochem Biophys Res Commun, 346:131–139.
36.
SongEJ, YooYS. 2011. Nerve growth factor-induced neurite outgrowth is potentiated by stabilization of TrkA receptors. BMB Rep, 44:182–186.
37.
FreemanRS, BurchRL, CrowderRJ, LombDJ, SchoellMC, StraubJA, XieL. 2004. NGF deprivation-induced gene expression: after ten years, where do we stand?Prog Brain Res, 146:111–126.
38.
LeeRJ, SpringerML, Blanco-BoseWE, ShawR, UrsellPC, BlauHM. 2000. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation, 102:898–901.
39.
ThurstonG. 2003. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res, 314:61–68.
40.
PreissnerKT, Grulich-HennJ, EhrlichHJ, DeclerckP, JustusC, CollenD, PannekoekH, Muller-BerghausG. 1990. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem, 265:18490–18498.
41.
XuJ, QuJ, CaoL, SaiY, ChenC, HeL, YuL. 2008. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol, 214:472–481.
42.
ChenSL, ZhuCC, LiuYQ, TangLJ, YiL, YuBJ, WangDJ. 2009. Mesenchymal stem cells genetically modified with the angiopoietin-1 gene enhanced arteriogenesis in a porcine model of chronic myocardial ischaemia. J Int Med Res, 37:68–78.
43.
ConradC, NiessH, HussR, HuberS, von LuettichauI, NelsonPJ, OttHC, JauchKW, BrunsCJ. 2009. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation, 119:281–289.
44.
HwangJH, KimIG, LeeJY, PiaoS, LeeDS, LeeTS, RaJC. 2011. Therapeutic lymphangiogenesis using stem cell and VEGF-C hydrogel. Biomaterials, 32:4415–4423.
45.
VeikkolaT, JussilaL, MakinenT, KarpanenT, JeltschM, PetrovaTV, KuboH, ThurstonG, McDonaldDMet al. 2001. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J, 20:1223–1231.
46.
BaldwinME, HalfordMM, RoufailS, WilliamsRA, HibbsML, GrailD, KuboH, StackerSA, AchenMG. 2005. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol, 25:2441–2449.
47.
RissanenTT, MarkkanenJE, GruchalaM, HeikuraT, PuranenA, KettunenMI, KholovaI, KauppinenRA, AchenMGet al. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res, 92:1098–1106.
48.
OhnishiS, YasudaT, KitamuraS, NagayaN. 2007. Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells, 25:1166–1177.
49.
FerraraN, Carver-MooreK, ChenH, DowdM, LuL, O'SheaKS, Powell-BraxtonL, HillanKJ, MooreMW. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 380:439–442.
50.
AchenMG, JeltschM, KukkE, MakinenT, VitaliA, WilksAF, AlitaloK, StackerSA. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)Proc Natl Acad Sci U S A, 95:548–553.
51.
JiaH, BagherzadehA, BicknellR, DuchenMR, LiuD, ZacharyI. 2004. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem, 279:36148–36157.
52.
VicennatiV, VotteroA, FriedmanC, PapanicolaouDA. 2002. Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord, 26:905–911.
53.
QianH, HausmanGJ, ComptonMM, AzainMJ, HartzellDL, BaileCA. 1998. Leptin regulation of peroxisome proliferator-activated receptor-gamma, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues. Biochem Biophys Res Commun, 246:660–667.
54.
MitchellSE, ReesWD, HardieLJ, HoggardN, TadayyonM, ArchJR, TrayhurnP. 1997. ob gene expression and secretion of leptin following differentiation of rat preadipocytes to adipocytes in primary culture. Biochem Biophys Res Commun, 230:360–364.
55.
IguchiM, AibaS, YoshinoY, TagamiH. 2001. Human follicular papilla cells carry out nonadipose tissue production of leptin. J Invest Dermatol, 117:1349–1356.
56.
HoggardN, HunterL, DuncanJS, WilliamsLM, TrayhurnP, MercerJG. 1997. Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta. Proc Natl Acad Sci U S A, 94:11073–11078.
57.
ChenSC, CunninghamJJ, SmeyneRJ. 2000. Expression of OB receptor splice variants during prenatal development of the mouse. J Recept Signal Transduct Res, 20:87–103.
58.
SumikawaY, NakajimaT, InuiS, ItamiS. 2008. Leptin is a paracrine regulator of hair cycle. J Invest Dermatol, 128:S146–S876.
59.
PoeggelerB, SchulzC, PappollaMA, BodoE, TiedeS, LehnertH, PausR. 2010. Leptin and the skin: a new frontier. Exp Dermatol, 19:12–18.
60.
LarcherF, Del RioM, SerranoF, SegoviaJC, RamirezA, MeanaA, PageA, AbadJLet al. 2001. A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. FASEB J, 15:1529–1538.
61.
MuradA, NathAK, ChaST, DemirE, Flores-RiverosJ, Sierra-HonigmannMR. 2003. Leptin is an autocrine/paracrine regulator of wound healing. FASEB J, 17:1895–1897.
62.
SchindlerR, MancillaJ, EndresS, GhorbaniR, ClarkSC, DinarelloCA. 1990. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood, 75:40–47.
63.
MukaidaN. 2000. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol, 72:391–398.
64.
ZhuY, LiuT, YeH, SongK, MaX, CuiZ. 2010. Enhancement of adipose-derived stem cell differentiation in scaffolds with IGF-I gene impregnation under dynamic microenvironment. Stem Cells Dev, 19:1547–1556.
VidalMA, KilroyGE, LopezMJ, JohnsonJR, MooreRM, GimbleJM. 2007. Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. Vet Surg, 36:613–622.
67.
MorettiP, HatlapatkaT, MartenD, LavrentievaA, MajoreI, HassR, KasperC. 2010. Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications. Adv Biochem Eng Biotechnol, 123:29–54.
68.
ChoiYS, MatsudaK, DustingGJ, MorrisonWA, DilleyRJ. 2010. Engineering cardiac tissue in vivo from human adipose-derived stem cells. Biomaterials, 31:2236–2242.
69.
PuxedduI, RibattiD, CrivellatoE, Levi-SchafferF. 2005. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol, 116:531–536.
70.
KochAE, PolveriniPJ, KunkelSL, HarlowLA, DiPietroLA, ElnerVM, ElnerSG, StrieterRM. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science, 258:1798–1801.
71.
KocherAA, SchusterMD, BonarosN, LietzK, XiangG, MartensTP, KurlanskyPA, SondermeijerH, WitkowskiPet al. 2006. Myocardial homing and neovascularization by human bone marrow angioblasts is regulated by IL-8/Gro CXC chemokines. J Mol Cell Cardiol, 40:455–464.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
